Streptococcus (e.g., Group B Streptococcus, Pneumococcus Or Streptococcus Pneumoniae, Etc.) Patents (Class 424/244.1)
  • Patent number: 10544197
    Abstract: Described herein are FGF-23 epitope peptides, methods of producing antibodies in laying hens by injecting the peptides, and methods of improving resistance to eggshell breakage and/or increasing eggshell strength by administering an FGF-23 epitope peptide to a laying hen.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: January 28, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mark Eric Cook, Zhouzheng Ren, Alexis Jo Piepenburg, Daniel Butz
  • Patent number: 10420826
    Abstract: Compositions comprising antigenic peptides, and their use in inducing an immunoprotective response in a subject against an infection with Streptococcus pneumonia, or for treating or preventing, i.e., reducing risk of, an infection of Streptococcus pneumonia.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: September 24, 2019
    Assignee: Massachusetts Eye & Ear Infirmary
    Inventors: Michael Valentino, Michael S. Gilmore
  • Patent number: 10392420
    Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: August 27, 2019
    Assignee: Pfizer Inc.
    Inventors: Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
  • Patent number: 10226524
    Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: March 12, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Vega Masignani, Marirosa Mora, Maria Scarselli
  • Patent number: 10035827
    Abstract: The present invention provides a recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH. Methods and medical devices for using utilizing the same are also described.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: July 31, 2018
    Assignee: The University Court of the University of Edinburgh
    Inventors: Paul Barlow, Andrew Herbert, Elisavet Makou
  • Patent number: 9981029
    Abstract: Provided is an immunogenic composition comprising 13 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from a different serotype Streptococcus pneumoniae conjugated to a carrier protein, that is, 12 serotypes selected from the group consisting of 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F and serotype 2 or 9N. The immunogenic composition formulated into a vaccine comprising an aluminum-based adjuvant increases coverage with respect to pneumococcal diseases in infants and children.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: May 29, 2018
    Assignee: SK Chemical Co., Ltd.
    Inventors: Mahn-Hoon Park, Hun Kim, Ji-Hye Yang, Seon-Young Yang, Myeong-Ju Noh, Su-Jin Park, Jin-Hwan Shin
  • Patent number: 9650425
    Abstract: Immunogenic group A streptococcus M-related polypeptides and peptides and immunogenic compositions comprising these M-related polypeptides and peptides are provided herein that evoke cross-opsonic and cross-protective anti-GAS and anti-SDSE antibodies in animals. Also provided are preparations comprising immunogenic compositions that comprise M-related polypeptides, peptides, or fusion proteins and that further comprise at least one additional group A streptococcus immunogen, such as an M peptide or Spa peptide.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: May 16, 2017
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: James B. Dale, Harry S. Courtney
  • Patent number: 9610339
    Abstract: The present invention relates to an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Methods of making and uses thereof are also described.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: April 4, 2017
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garçon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Patent number: 9610340
    Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: April 4, 2017
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garçon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Patent number: 9441004
    Abstract: The invention provides a method for releasing capsular polysaccharide from S. aureus type 5 or type 8 cells, comprising the step of treating the cells with acid. The invention further provides a process for purifying capsular polysaccharide from S. aureus type 5 or type 8 cells comprising this method. Other processing steps may be included in the process, such as enzymatic treatment, e.g. to remove nucleic acid, protein and/or peptidoglycan contaminants; diafiltration, e.g. to remove low molecular weight contaminants; anion exchange chromatography, e.g. to remove residual protein; and concentration.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: September 13, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Paolo Costantino, Maria Rosaria Romano, Francesco Berti
  • Patent number: 9370557
    Abstract: The invention relates to the use of bacterial cytolysin proteins, such as pneumolysin, as adjuvants for stimulating or enhancing immune responses against co-administered target antigens. Desirably, the target antigen is provided as a fusion protein with the cytolysin. The inventors have found that cytolysins may be particularly effective for stimulation of mucosal immune responses against the target antigen.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: June 21, 2016
    Assignee: The University Court of the University of Glasgow
    Inventors: Timothy John Mitchell, Lea-Ann Kirkham, Graeme James Cowan, Gillian Douce
  • Patent number: 9340586
    Abstract: The present invention relates to antigens more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: May 17, 2016
    Assignee: ID BIOMEDICAL CORPORATION OF QUEBEC
    Inventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
  • Patent number: 9289485
    Abstract: A method for treating rheumatic heart disease comprising administering an immunogenic composition against group A beta hemolytic streptococcus.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: March 22, 2016
    Inventors: Luiza Guilherme Guglielmi, Jorge Elias Kalil Filho
  • Patent number: 9147041
    Abstract: A dashboard user interface method comprises displaying a navigable list of at least one target disease, displaying a navigable list of patient identifiers associated with a target disease selected in the target disease list, displaying historic and current data associated with a patient in the patient list identified as being associated with the selected target disease, including clinician notes at admission, receiving, storing, and displaying review's comments, and displaying automatically-generated intervention and treatment recommendations.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: September 29, 2015
    Assignee: Parkland Center for Clinical Innovation
    Inventors: Rubendran Amarasingham, Timothy S. Swanson, Sambamurthy Nalla, Yu Qian, George R. Oliver, Kimberly P. Gerra
  • Patent number: 9125863
    Abstract: An immunogenic composition comprising a fusion protein-polysaccharide conjugate consisting of a polysaccharide (PS) or pneumococcal bacterial cell wall polysaccharide (CWPS) conjugated to X:PdT where PdT represents the nonhemolytic variant of pneumolysin and X represents an antigenic peptide or protein of interest is provided. The immunity to X is synergistically enhanced by the fusion conjugate. Methods of protecting a subject from pneumococcal colonization or disease by administering an immunogenic composition including a fusion protein (PsaA:PdT) containing truncated PsaA and the nonhemolytic variant of pneumolysin (PdT) conjugated with CWPS (PsaA:PdT-CWPS) is also provided.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: September 8, 2015
    Assignee: Children's Medical Center Corporation
    Inventors: Ying-jie Lu, Richard Malley
  • Patent number: 9085634
    Abstract: The present invention relates to the use of a peptide of P0 ribosomal protein in the manufacture of a vaccine composition to control of ectoparasite infestations and therefore the transmission of their associated pathogens. This peptide is located between 267 and 301 amino acids of the P0 protein, and can be obtained by recombinant means or by chemical synthesis. This peptide can be fused to a carrier protein or peptide, or an immuno-carrier and be included in an oily formulation. The formulations comprising the peptide vaccine confer protection against ticks and ectoparasites known as “sea lice” without generating autoimmunity in the host organism. Among these ticks may be mentioned species as Rhipicephalus microplus, Rhipicephalus sanguineus and Ixodes scapularis, and between sea lice are those of the Caligus and Lepeophtheirus genera.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: July 21, 2015
    Assignee: Centro de Ingeniería Genética y Biotecnología
    Inventors: Alina Rodriguez Mallon, Erlinda Fernández Díaz, Mario Pablo Estrada Garcia, Yamila Carpio González
  • Patent number: 9085610
    Abstract: Helicobacter pylori, one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a ?1,6-glucan-containing Helicobacter pylori compound comprising the structure of Formula (I): wherein R is a ?-DDHep-3-?-L-Fuc-3-?-GlcNAc trisaccharide substituted with an ?1,6-glucan linked to an ?1,3-DD-heptan, and wherein the last DD-Hep residue of ?1,3-DD-heptan is capped with ?-GlcNAc residue. Compositions comprising the compound, uses of the compound, and antibodies raised against the compound are also described.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: July 21, 2015
    Assignee: National Research Council of Canada
    Inventors: Eleonora Altman, Blair A. Harrison, Vandana Chandan
  • Patent number: 9078842
    Abstract: Disclosed are methods of altering metabolism of phosphate in a livestock via an antibody. The methods involve the development of an antibody against FGF-23 for the purpose of reducing phosphate excretion by an animal.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: July 14, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Mark E. Cook, Elizabeth A. Bobeck, Kimberly S. Burgess
  • Patent number: 9056912
    Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: June 16, 2015
    Assignee: Novartis Vaccines and Diagnostics, SRL
    Inventors: Guido Grandi, John Telford, Giuliano Bensi
  • Patent number: 9040057
    Abstract: A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of S. pneumoniae strains CGSP14, wherein administration of the recombinant pneumococcal neuraminidases elicits an immune response to S. pneumoniae, and treats the subject. In one embodiment, the method further includes a step of adding adjuvants to enhance the immune response. The method also includes a step of using passive antibodies, wherein said passive antibodies are anti-neuraminidase antibodies generated from neuraminidases-immunized humanized animals: NanA, NanB, and NanC. Meanwhile, this invention also provides a method for the molecular diagnosis of pneumococcal infection.
    Type: Grant
    Filed: September 25, 2011
    Date of Patent: May 26, 2015
    Assignee: CHANG GUNG MEDICAL FOUNDATION, LINKOU BRANCH
    Inventors: Cheng-Hsun Chiu, Rajendra Prasad Janapatla, Chyi-Liang Chen, Mei-Hua Hsu, Hsiu-Ling Chen, Chung-Tsui Huang, Hsin-Ju Chang, Wan-Ting Liao
  • Publication number: 20150140036
    Abstract: The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 21, 2015
    Applicant: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
    Inventors: Joan Mannick, David Glass, Leon Murphy
  • Publication number: 20150132339
    Abstract: The efficacy of S. pneumoniae vaccines can be enhanced by adjuvanting S. pneumoniae saccharide and/or protein antigens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. The S. pneumoniae antigen can also be adsorbed to the metal salt.
    Type: Application
    Filed: March 7, 2013
    Publication date: May 14, 2015
    Inventors: Simone Bufali, Paolo Costantino, Michele Pallaoro, Derek O'hagan, Rino Rappuoli, Manmohan Singh
  • Patent number: 8999697
    Abstract: A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified S. pneumoniae lysate followed by pH adjustment to less than 4.5, preferably about 3.5, precipitated at least 98% of the protein in the solution without seriously affecting polysaccharide yield. Furthermore, following ultrafiltration and diafiltration and acidification to a pH of less than 4.5, filtration using activated carbon precipitated at least 90% of remaining protein without seriously affecting polysaccharide yield. Exemplary, non-limiting S. pneumoniae serotypes that can be purified using the shortened process of the invention are 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: April 7, 2015
    Assignee: Wyeth LLC
    Inventors: Yonghui Yuan, Mark Ruppen, Wei-Qiang Sun, Ling Chu, John Simpson, James Patch, Justin Keith Moran, Pamela Fink Charbonneau
  • Patent number: 8993624
    Abstract: The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: March 31, 2015
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Josep Bassaganya-Riera, Amir Guri, Raquel Hontecillas
  • Publication number: 20150079132
    Abstract: This disclosure is directed to compositions that combine the polysaccharide-specific antibody protection afforded by the conventional vaccines through carrier effects provided by one or more pneumococcal common T-cell antigen(s) together with Streptococcus pneumoniae-specific Th-17 responses elicited by the pneumococcal carrier common T-cell antigen. The disclosed compositions are useful for pan-serotypic protection against NP carriage, and antibody responses against common pneumococcal virulence factors, potentially useful for pan-serotype protection against Streptococcus pneumoniae invasive diseases.
    Type: Application
    Filed: September 17, 2014
    Publication date: March 19, 2015
    Applicant: PATH
    Inventors: Jean-Francois Lucien Maisonneuve, Mark Raymond Alderson
  • Patent number: 8945589
    Abstract: This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment thereof. In one embodiment, the combination may consist of two to thirteen GBS antigens selected from an antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 184, GBS 276, GBS 305, GBS 322, GBS 330, GBS 338, GBS 361, GBS 404, GBS 690, and GBS 691.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: February 3, 2015
    Assignee: Novartis Vaccines and Diagnostics, SRL
    Inventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
  • Patent number: 8945568
    Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6D, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?4) ribitol (5?phosphate. This new serotype may be included in pneumococcal vaccines.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: February 3, 2015
    Assignee: The UAB Research Foundation
    Inventors: Moon H. Nahm, In Ho Park
  • Publication number: 20150017209
    Abstract: This disclosure relates to a method of preventing or treating a recurrence of acute otitis media in a subject at risk comprising administering a therapeutically effective amount of a composition, at least once to the subject.
    Type: Application
    Filed: December 2, 2011
    Publication date: January 15, 2015
    Applicant: SANOFI PASTEUR LIMITED
    Inventor: Michael Pichichero
  • Patent number: 8926985
    Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: January 6, 2015
    Assignee: GlaxoSmithKline Biologicals S A
    Inventors: Carine Capiau, Marguerite Deschamps, Pierre Michel Desmons, Craig Antonyjoseph Laferriere, Jan Poolman, Jean-Paul Prieels
  • Publication number: 20140377309
    Abstract: The present invention relates to the field of immunology. The present invention provides agonists and antagonists of Toll-like receptor (TLR) 13. In particular, the present invention provides TLR13 activating and inhibiting nucleic acids, and provides such nucleic acids for use as pharmaceutical agents. The present invention further provides in vitro methods using such nucleic acids.
    Type: Application
    Filed: February 8, 2013
    Publication date: December 25, 2014
    Inventors: Carsten Kirschning, Stefan Bauer, Hubertus Hochrein
  • Publication number: 20140363463
    Abstract: A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified S. pneumoniae lysate followed by pH adjustment to less than 4.5, preferably about 3.5, precipitated at least 98% of the protein in the solution without seriously affecting polysaccharide yield. Furthermore, following ultrafiltration and diafiltration and acidification to a pH of less than 4.5, filtration using activated carbon precipitated at least 90% of remaining protein without seriously affecting polysaccharide yield. Exemplary, non-limiting S. pneumoniae serotypes that can be purified using the shortened process of the invention are 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
    Type: Application
    Filed: January 24, 2014
    Publication date: December 11, 2014
    Applicant: Wyeth LLC
    Inventors: Yonghui YUAN, Mark RUPPEN, Wei-Qiang SUN, Ling CHU, John SIMPSON, James PATCH, Justin Keith MORAN, Pamela FINK CHARBONNEAU
  • Patent number: 8906630
    Abstract: The present invention encompasses methods, assays and kits for the detection of pathogenic bacteria in a patient and for the differential diagnosis of pulmonary diseases associated with pathogenic bacteria from pulmonary diseases not associated with pathogenic bacteria.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: December 9, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jeffrey N. Weiser, Jane M. Gould
  • Patent number: 8895024
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: November 25, 2014
    Assignee: Wyeth LLC
    Inventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
  • Publication number: 20140314812
    Abstract: The present invention is an attenuated mutant strain of Streptococcus pneumonia that has a mutation in the FtsY gene. Vaccines, kits and methods for protecting a subject against Streptococcus pneumonia disease or colonization using the attenuated mutant strain are also provided.
    Type: Application
    Filed: September 19, 2012
    Publication date: October 23, 2014
    Inventors: Jason W. Rosch, Elaine I. Tuomanen, Jonathan A. McCullers
  • Patent number: 8858957
    Abstract: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 14, 2014
    Assignee: Novartis AG
    Inventors: Immaculada Margarit Y Ros, Guido Grandi, Chiara Zingaretti
  • Patent number: 8852606
    Abstract: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilized using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilization of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: October 7, 2014
    Assignee: Novartis AG
    Inventor: Paolo Costantino
  • Publication number: 20140294930
    Abstract: In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.
    Type: Application
    Filed: August 3, 2012
    Publication date: October 2, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Victor Nizet, Nina van Sorge
  • Publication number: 20140287043
    Abstract: Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.
    Type: Application
    Filed: April 23, 2012
    Publication date: September 25, 2014
    Applicant: TRUSTEES OF TUFTS COLLEGE
    Inventors: David L. Kaplan, Fiorenzo Omenetto
  • Patent number: 8828409
    Abstract: A method for immunizing a human or animal against pneumococcal infections, comprising by administering a vaccine comprising a purified recombinant caseinolytic protease P (ClpP) protein of S. pneumoniae in an immunologically effective amount to the human or animal.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: September 9, 2014
    Assignees: Sungkyunkwan University, Adelaide Research & Innovation Pty Ltd.
    Inventors: Dong-Kwon Rhee, Hyeok-Young Kwon, Mu-Hyeon Choi, Abiodun David Ogunniyi, James Cleland Paton
  • Patent number: 8821895
    Abstract: The present invention relates to antigens, more particularly antigenS of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for therapy and/or prophylaxis.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: September 2, 2014
    Assignee: ID Biomedical Corporation of Quebec
    Inventors: Denis Martin, Bernard R. Brodeur, Josee Hamel, Stephane Rioux, Patrick Rheault
  • Patent number: 8815254
    Abstract: The present invention relates to a method of detoxifying bacterial cytolysins such as pneumococcal pneumolysin, utilizing chemical cross-linking compounds.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: August 26, 2014
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Ralph Biemans, Karine Goraj, Emmanuel Mertens, Annick Vandercammen
  • Patent number: 8808704
    Abstract: The embodiments described herein provide for immunogenic portions of Streptococcus pneumoniae surface protein A and surface protein C lacking alpha helical structure.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: August 19, 2014
    Assignee: The UAB Research Foundation
    Inventors: Susan K. Hollingshead, David E. Briles
  • Publication number: 20140220065
    Abstract: A method for treating rheumatic heart disease comprising administering an immunogenic composition against group A beta hemolytic streptococcus
    Type: Application
    Filed: February 3, 2014
    Publication date: August 7, 2014
    Inventors: LUIZA GUILHERME GUGLIELMI, JORGE ELIAS KALIL FILHO
  • Patent number: 8795690
    Abstract: The invention relates to a composition comprising at least two protective proteins against Streptococcus agalactiae (S. agalactiae) or functionally active variant thereof; a protective peptide against S. agalactiae; one or more nucleic acid(s) encoding the at least two proteins and/or the protective peptide; a method of producing the composition; a pharmaceutical composition, especially a vaccine, comprising the composition and/or at least one protective peptide; methods for producing antibodies; a mixture of antibodies against the at least two proteins of the composition; the use of the composition and/or at least one protective peptide and/or one or more nucleic acid(s) for the manufacture of a medicament for the immunization or treatment of a subject; methods of diagnosing a S.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: August 5, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Beatrice Tschanun, Eszter Nagy, Andreas Meinke, Alexander Von Gabain, Barbara Maierhofer, Ulrike Stierschneider, Manfred Berger, Christina Neubauer, Katherine Cohen
  • Patent number: 8795689
    Abstract: The present invention provides improved methods for producing a solution containing high molecular weight isolated Streptococcus pneumoniae 19A capsular polysaccharides. In certain methods, a fermentation culture of Streptococcus pneumoniae bacterial cells that produce serotype 19A capsular polysaccharides is fermented for less than 6 hours before the bacterial cells are lysed the capsular polysaccharides are harvested. In other methods, CO2 is supplied to the fermentation culture. Supplying CO2 to the fermentation culture includes adding bicarbonate ions to the fermentation culture, adding carbonate ions to the fermentation culture, adding mixtures of bicarbonate and carbonate ions to the fermentation culture, and overlaying the fermentation culture with CO2.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: August 5, 2014
    Assignee: Wyeth LLC
    Inventor: Jean Heather Crinean
  • Patent number: 8790658
    Abstract: Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions, reconstituted liquid formulations of the vitreous compositions, vaccine compositions, and kits containing the vitreous compositions. Also disclosed are devices for administering the vitreous compositions to mammals and methods for eliciting an immune response in mammals by administering the compositions.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: July 29, 2014
    Assignee: Sanofi Pasteur Limited
    Inventors: Sandrine Cigarini, Kevin Harper, Manvi Hasija
  • Publication number: 20140205634
    Abstract: Methods of treating a Streptococcus pneumoniae infection are described herein.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 24, 2014
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe DENOEL, Philippe Vincent HERMAND, Steve LABBE, Jan POOLMAN, Stephane RIOUX
  • Patent number: 8778358
    Abstract: The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: July 15, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Cira Daniela Rinaudo, Domenico Maione
  • Patent number: RE45170
    Abstract: The invention relates to Streptococcus suis infection in pigs, vaccines directed against those infections and tests for diagnosing Streptococcus suis infections. The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of Streptococcus suis or a gene or gene fragment derivated thereof. The invention further provides a nucleic acid probe or primer allowing species or serotype-specific detection of Streptococcus suis. The invention also provides a Streptococcus suis antigen and vaccine derived thereof.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: September 30, 2014
    Assignee: Stichting Dienst Landbouwkundig Onderzoek
    Inventor: Hilda Elizabeth Smith
  • Patent number: RE45467
    Abstract: The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same which are involved in the pathogenic mechanism of S. suis. The present invention also relates to the use of such polypeptides in compositions and methods for the prevention, the treatment and diagnosis of S. suis-associated diseases and infections caused by S. suis.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: April 14, 2015
    Assignee: Valorisation-Recherche, Limited Partnership
    Inventors: Josee Harel, Marcelo Gottschalk, Yuanyi Li